• Who we are
Multispecific yet truly natural antibodies

Taking next generation, multispecific antibody technologies into Alzheimer’s Disease and Antimicrobial Resistance

Taking next generation, multispecific antibody technologies into Alzheimer’s Disease and Antimicrobial Resistance

Who we are
Who we are

Long term pharma and biotech professionals with a track record of leading projects from research into the market

Our antibody development roots go deep

Our focus
Our focus

Multispecific yet natural

Alzheimer’s Disease and Antimicrobial Resistance

CD47 Dual targeting
Our pipeline

Fully human bi- and multi-specific antibodies for the treatment of Alzheimer’s Disease and Antimicrobial Resistant infections

Safe and selective blockade of CD47 on tumors

Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

previous arrow
next arrow

Jean Philippe Courade, CSO discoveric bio alpha and discoveric bio gamma

Jean-Philippe is a Neuroscientist development specialist and serves as CSO to discoveric bio alpha and discoveric bio gamma.

Before joining discoveric bio, he led the tau antibody research project in UCB and is one of the inventor of UCB0107 / Bepranemab which is now in clinical development for Alzheimer’s Disease and Progressive Supranuclear Palsy.

Earlier in his career he was a Neuroscientist and led projects in the chronic pain field in Novartis and Pfizer. Jean-Philippe studied in University Pierre and Marie Curie (Paris 6) and is a neuropharmacologist by training and holds a PhD from University of Auvergne-financed by UPSA/BMS.

Jean-Philippe Courade

Back